Literature DB >> 9175921

Screening of SLE sera using purified recombinant Sm-D1 protein from a baculovirus expression system.

Y Ou1, D Sun, G C Sharp, S O Hoch.   

Abstract

The Sm-D1 polypeptide is a major target of autoantibodies diagnostic for systemic lupus erythematosus (SLE). The cDNA encoding the human antigen was expressed as a full-length, nonfusion protein using a eukaryotic baculovirus expression system. This recombinant version of Sm-D1 (rSm-D1) was purified to apparent homogeneity by a combination of differential extraction steps and FPLC chromatography. A direct antibody-binding ELISA was developed using the purified antigen. There was 96% correlation between the rSm-D1 and bona fide Sm-D1 from either HeLa cells or rabbit thymus when tested against Sm-positive patient sera by ELISA. The baculovirus-expressed Sm-D1 is reactive not only with patient anti-Sm sera, but also with anti-Sm monoclonal antibodies. Our results suggest that this rSm-D1 mimics the bona fide sources, providing a valuable addition to the roster of antigens available for SLE screening, epitope mapping and overall structure study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175921     DOI: 10.1006/clin.1997.4355

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

1.  Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay.

Authors:  M Mahler; L M Stinton; M J Fritzler
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

2.  A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus.

Authors:  G Riemekasten; J Marell; G Trebeljahr; R Klein; G Hausdorf; T Häupl; J Schneider-Mergener; G R Burmester; F Hiepe
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

3.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

4.  Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies.

Authors:  Michael Mahler; Marvin J Fritzler; Martin Blüthner
Journal:  Arthritis Res Ther       Date:  2004-11-10       Impact factor: 5.156

5.  Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE.

Authors:  Chaojun Hu; Mengtao Li; Jian Liu; Junyan Qian; Dong Xu; Shulan Zhang; Ping Li; Jiulang Zhao; Xinping Tian; Xiaofeng Zeng
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

6.  The DNA co-vaccination using Sm antigen and IL-10 as prophylactic experimental therapy ameliorates nephritis in a model of lupus induced by pristane.

Authors:  Beatriz Teresita Martín-Márquez; Minoru Satoh; Rogelio Hernández-Pando; Erika Aurora Martínez-García; Marcelo Heron Petri; Flavio Sandoval-García; Oscar Pizano-Martinez; Trinidad García-Iglesias; Fernanda Isadora Corona-Meraz; Monica Vázquez-Del Mercado
Journal:  PLoS One       Date:  2021-10-27       Impact factor: 3.240

7.  Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus.

Authors:  Michael Mahler; Aderajew Waka; F Hiepe; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.